In one such study [124], targeting survivin, a member of the inhibitor of apoptosis protein (IAP) family, using HIV-1 TAT peptides to disrupt the phosphorylation of survivin by cyclin-dependent kinase 1 abrogated the TCS response seen in H1299 lung cancer cells that had been treated with the anticancer drug camptothecin and instead triggered an apoptotic response. Here, BIRC5 is linked to lung carcinoma.